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The blockade of tumour vascularisation and angiogenesis continues to be a focus for drug development
in oncology and other pathologies. Historically, targeting vascular endothelial growth factor (VEGF)
activity and its association with VEGF receptors (VEGFRs) has represented the most promising line of
attack. More recently, the recognition that VEGFR co-receptors, neuropilin-1 and -2 (NRP1 and NRP2),
are also engaged by specific VEGF isoforms in tandem with the VEGFRs has expanded the landscape for
the development of modulators of VEGF-dependent signalling. Here, we review the recent structural
characterisation of VEGF interactions with NRP subdomains and the impact this has had on drug
development activity in this area.Introduction
Angiogenesis, the physiological process of new blood vessel for-
mation, is an essential component of tumour progression. Tumour
growth relies on the development of new vasculature to provide
oxygen and nutrients to the proliferating cells while removing
carbon dioxide and metabolic waste. Targeting angiogenesis has
emerged as a prominent strategy to complement chemotherapeu-
tic approaches to treat cancer [1–3]. A pivotal pro-angiogenic
signalling molecule is vascular endothelial growth factor A
(VEGF-A) which promotes proliferation, survival, migration and
permeability of endothelial cells lining the inner layer of blood
vessels [4]. The creation and maintenance of the vasculature not
only supports rapid growth of malignant tumours but also
increases metastatic potential of cancer by providing a route for
the escape and travel of malignant cells to remote sites in the body.
An increased level of circulating VEGF is directly correlated to a
poor patient outcome. In other contexts angiogenesis is an instru-
mental physiological response to inflammation, and it has a
central role in eye diseases such as age-related macular degenera-
tion and diabetic retinopathy. Here again, blood vessel formation,
maintenance and permeability are regulated via VEGF signalling,
providing a potential target for therapeutic intervention.Corresponding author:. Djordjevic, S. (s.djordjevic@ucl.ac.uk)
1359-6446/06  2012 Elsevier Ltd. http://dx.doi.org/10.1016/j.drudis.2012.11.01Open access under CC BY license.VEGFs and VEGFRs
The VEGF family of secreted glycoproteins comprises VEGF-A,
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor
(PGF) (Fig. 1). The best-characterised variant, VEGF-A is linked to
important physiological processes such as wound healing, preg-
nancy and maintenance of blood pressure, as well as various
pathologies dependent upon angiogenesis including cancer [4–
6]. Alternative splicing of the VEGF-A gene produces several iso-
forms of the mature protein containing between 121 and 206
amino acid residues, with VEGF-A165 being the dominant isoform
responsible for pathological angiogenesis [7,8]. VEGFs exert their
activity through interaction with a family of three transmem-
brane tyrosine kinase receptors, the VEGF receptors (VEGFRs)
[9,10]. The individual VEGF isoforms bind to the VEGFRs with
differing affinity and the combinatorial nature of the growth-
factor-receptor signalling complexes mediates a range of cellular
responses (Fig. 1). In the endothelium, the pro-angiogenic func-
tion of VEGF-A is mediated primarily via interaction with
VEGFR2, also known as kinase insert domain-containing receptor
(KDR) [11]. VEGF binding to VEGFR2 is associated with receptor
dimerisation and activation that triggers downstream signalling
pathways including phosphatidylinositol 3-kinase (PI3-K)/Akt
and phospholipase C gamma/extracellular signal-regulated
kinase (PLCg/ERK) cascades that, together, support cell survival3 www.drugdiscoverytoday.com 447
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FIGURE 1
(a) Schematic representation of the family of VEGF-A splice isoforms indicating the exon-based origin of the domain organisation. The VEGFR binding domain
derives from exons 2–5, the two-module heparin binding domain from exons 6 and 7 and the extreme C-terminal tail region (six amino acid residues) from exon
8. (b) VEGF proteins are disulphide-crosslinked (red) antiparallel homodimers, indicated here for VEGF-A165. (c) Outline domain structure of VEGFR and
NRP isoforms, drawn as transmembrane monomers (left). Cartoon representation (right) illustrating how VEGF-A165 might crosslink VEGFR2 and NRP1 to effect
signalling, principally through trans-autophosphorylation of the VEGFR2 cytoplasmic domain. The position of glycosaminoglycans, implicated in complex
formation, is not shown, as is the engagement of the NRP1 C-terminal region with putative binding partners, or the potential for direct contacts between the
ectodomains of VEGFR2 and NRP1.
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VEGF signalling such as cell migration, blood vessel guidance
and branching involve the formation of a more complex receptor
assembly containing the VEGFR2 co-receptor neuropilin (NRP)
[12,13].
In principle, interference of VEGF signalling, arguably the most
direct and practical way to inhibit angiogenesis, can be carried out
either through suppression of the activity of VEGF itself or through
the blockade of VEGFR function. Both of these strategies have been
explored experimentally. For example, removal of VEGF from the
circulation is the mechanism of action of the first commercially
available angiogenesis inhibitor bevacizumab, a specific huma-
nised monoclonal antibody [14,15]. Bevacizumab (Avastin1) is
approved for the treatment of certain metastatic cancers and,
despite some reservations regarding safety and effectiveness
[16,17], further clinical trials are underway to investigate other
potential uses of this antibody in cancer and in eye disease.
Removal of VEGFs from the circulation has also been achieved
with so-called ‘VEGF traps’ comprising engineered soluble VEGFR
fragments. One of these, aflibercept, recently gained FDA approval
for the treatment of age-related macular degeneration [18,19].
Similarly, it was reported that a mutated soluble NRP2 can reduce
VEGF bioactivity [20]. In addition, some therapeutic success has
been achieved by targeting VEGF receptor function through the448 www.drugdiscoverytoday.comdevelopment of antibodies that block ligand binding or VEGFR
dimerisation, and with small molecule inhibitors of the intracel-
lular receptor tyrosine kinase activity [21–27]. For example, sor-
afenib [23,24] and sunitinib [25–27] have been approved for use
against advanced stage renal cell carcinoma. However, these mole-
cules exhibit limited specificity: they not only interact with
VEGFR2 but also with the platelet-derived growth factor (PDGF)
receptor kinase and Raf kinase [28].
Ever since Folkman’s hypothesis that inhibition of angiogenesis
in solid tumours could be used to treat cancer [2], many potential
inhibitors have been tested and currently there are numerous
antiangiogenic therapeutics in development or undergoing clin-
ical trials [1,15,29]. Unfortunately, many of the VEGF and/or
VEGFR inhibitors tested so far have been reported to exhibit
limited efficacy and high toxicity with problems including hyper-
tension, protein in urine and arterial blood clots that can lead to
stroke or heart attack, and result in only a mild improvement in
patient survival [3,16,17,30–32]. New approaches to confront
cancer-associated angiogenesis are being explored [33,34]. In par-
ticular, it would be desirable to achieve higher selectivity of VEGF-
signalling inhibitors to eliminate off-target activity and thereby
reduce toxicity. In the search for relevant new approaches, NRP1
has emerged as an attractive target owing to its role as a co-receptor
for VEGF-A alongside VEGFR2. Here, we describe the molecular
Drug Discovery Today  Volume 18, Numbers 9/10 May 2013 REVIEWS
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exploitation.
NRP: history and target validation
The NRPs, single-pass transmembrane receptors, originally discov-
ered in the Xenopus nervous system [35], are highly conserved
among vertebrates. In humans, the two related proteins NRP1 and
NRP2 exhibit 44% sequence identity. NRPs are differentially
expressed with NRP1 found primarily in arterial endothelial cells,
whereas NRP2 expression is localised to venous and lymphatic
endothelium. In addition, the two proteins exhibit differences in
the subset of ligands that they recognise; for example, aside from
VEGFs, NRP1 is a receptor for semaphorin-3A, -3C and -3F, whereas
NRP2 preferentially binds semaphorin-3B, -3C, -3D and -3F [36–
39]. Class 3 semaphorins are members of a family of axon guidance
molecules that signal by interaction with transmembrane receptor
complexes that incorporate NRPs as co-receptors to plexins –
major receptors for all semaphorin family members. NRPs also
recognise various VEGFs that, compared to semaphorins, represent
a rather distinct set of ligands. Similar to the situation with
semaphorins, there is distinct preference between the NRPs for
different subsets of VEGFs. NRP1 interacts with heparin-binding
isoforms of VEGF-A, -B, -E and PGF, whereas NRP2 interacts with
VEGF-A, -C and -D [40–42]. VEGF–NRP binding is manifested
primarily in the context of the NRP having a co-receptor role
alongside the VEGF receptor.
The difference in expression patterns along with the distinct
agonist specificity are reflected in the separate physiological roles
that NRP1 and NRP2 have in development and disease. NRP1 gene
deletion in mice results in embryonic lethality with embryos
exhibiting abnormalities in heart, vasculature and neuronal gui-
dance [43–45]. By contrast, NRP2-deficient mice are viable,
although smaller in size than wild-type, and they display minor
abnormalities in the lymphatic system [46]. Double knockout
mice show an even more severe phenotype and die in utero at
day E8.5 [47]. Most of the effects from the mutant mouse models
point toward interaction of the VEGF-A165 isoform with NRP1 in
endothelial cells and semaphorin-3A and/or semaphorin-3F with
NRP1 and/or NRP2 in the nervous system [43–48].
The presence of NRPs has also been demonstrated in cancer cell
lines as well as in various primary tumours. NRP1 participates in an
autocrine VEGF165-dependent signalling mechanism that pro-
motes breast cancer [49,50]. Preclinical studies support a role for
tumour cell NRP1 in lung and renal cancer cell migration, pro-
liferation and invasion [51,52]. Recently, it was shown that NRP1
is essential in skin tumourigenesis, because NRP1 deletion abro-
gated the response of cancer stem cells to autocrine VEGF [53].
NRP1 also appears to support proliferation of human glioma stem-
like cells in glioblastoma multiforme [54].
Many research groups have investigated NRP expression pat-
terns and generated evidence for NRPs in endothelial and tumour
cells [39,49,55–60]. Recently, a comprehensive evaluation of NRP1
expression was carried out for breast, colorectal and lung cancer
[61]. In this study, a validated, highly specific monoclonal anti-
body was used for in situ analysis of NRP1 expression in cancerous
tissue and during normal developmental angiogenesis. NRP1 was
detected in more than 98% of blood vessels associated with
primary and metastatic lung, colorectal and breast tumours. Bycontrast, the pattern of NRP1 expression on tumour cells them-
selves is much more varied: NRP1 was detected on 6% of primary
breast carcinomas, 14% of secondary breast carcinomas, 36% of
primary non-small-cell lung cancers (NSCLCs) and 50% of sec-
ondary NSCLCs; there was no NRP1 detectable on colorectal
cancer cells. When the same antibody was used for the analysis
of NRP1 expression during mouse development, NRP1 was found
throughout the endocardial endothelium, whereas expression in
the vasculature of other tissues was only detected in localised areas
[61]. In addition, NRP1 was detected in the nervous system,
smooth muscle cells and pericytes. Furthermore, blockade of
NRP1 signalling resulted in defective VEGF-dependent angiogen-
esis in the postnatal mouse trachea providing further support for
the hypothesis that NRP1 is a valid antiangiogenic target and
potential antitumour target in at least a subset of cancers.
Additional NRP1 functions
There is a growing amount of evidence available that suggests NRP1
might display separate functions through mechanisms that might
not involve VEGFR2. For example, suppression of NRP1 protein
levels via siRNA results in changes in endothelial cell adhesion
properties, whereas the same effect is not reproduced by siRNA
knockdown of VEGFR2. It appears that NRP1 supports endothelial
cell matrix adhesion through interaction with integrins in a VEGF-
dependent manner [62–64]. Additionally, several studies have
shown that NRP1 might signal through other receptor tyrosine
kinases in response to ligands such as hepatocyte growth factor
(HGF) and PDGF. It was reported that NRP1 and NRP2 mediate HGF-
activated endothelial cell migration and proliferation [65] and that
NRP1 interaction with PDGF-BB (the dimeric B-form of PDGF)
stimulates migration of smooth muscle cells [66]. An increase in
tyrosine phosphorylation of a scaffolding protein p130Cas, down-
stream of the kinase Pyk2, appears to be the major output of NRP1
signalling in response to HGF and PDGF in U87 glioma cells [67,68]
and in human coronary artery vascular smooth muscle cells [69].
p130Cas tyrosine phosphorylation is linked to control of cell migra-
tion and is reduced upon NRP1 knockdown by siRNA. The activa-
tion of p130Cas seems to be dependent upon the cytoplasmic region
of NRP1 because inhibition of VEGF-induced p130Cas tyrosine
phosphorylation was also observed in experiments involving over-
expression of NRP1 lacking its entire cytoplasmic region [67]. In
addition, the cytoplasmic domain was implicated in a VEGF-depen-
dent regulation of spatial separation of arteries and veins [70]. A
knockin mouse model expressing NRP1 lacking the cytoplasmic
domain showed atypically frequent occurrence of crossover of veins
and arteries with no abnormalities in vasculogenesis and angiogen-
esis, suggesting that the cytoplasmic domain of NRP1 is required for
normal arteriovenous patterning [70]. Furthermore, it was sug-
gested that the NRP1 has VEGF165- and/or semaphorin-3A-indepen-
dent activity in regulating a5b1-integrin traffic and downstream
signalling [63]. NRP1 has also been implicated in signalling that
leads to Pyk2-dependent phosphorylation at the Tyr407 site of focal
adhesion kinase (FAK) [67] and activation of p38 mitogen-activated
protein kinase (MAPK) which is involved in formation of pericyte-
associated vessels [71]. These studies are however at an early stage;
further investigation of the signalling pathways that operate down-
stream of NRP1 and the precise co-receptor context for these events
is required to resolve the apparent complexity.www.drugdiscoverytoday.com 449
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NRPs are type 1, single-pass, transmembrane proteins with a large
(>920 amino acid residues) extracellular region comprising five
modular domains named a1, a2, b1, b2 and c, joined to a trans-
membrane helical region and a short (44 residue) cytoplasmic
domain [37] (Fig. 1). The different extracellular domains each
share similarity to functionally diverse structural modules com-
monly found in cell-surface receptors and proteins involved in
mediating cellular interactions (Figs 1 and 2a). The tandem a
domains (a1a2) belong to the structural family of C1r/C1s-Uegf-
BMp1 (CUB) domains homologous to complement binding factors
C1r and C1s. The b1 and b2 domains are homologous to the C1
and C2 (discoidin) domains of coagulation factors FV and FVIII.
The membrane-proximal c domain of NRP belongs to the family of
MAM domains (meprin, A-5 protein and receptor protein tyrosine
phosphatase m) that have been implicated in protein homodimer-
isation. A single transmembrane helix that is reported to mediate
NRP1 dimerisation [72] links the modular ectodomain to the
intracellular region, the structure of which is unknown. It has
been shown that the extreme C-terminal tripeptide (-Ser-Glu-Ala-
COOH) is required for NRP1 interaction with the PDZ domain of
synectin (also known as NIP or GIPC), a protein that is reported to
play a part in the regulation of arterial branching [73–75]. Several
reports confirm the important contribution of the NRP1 cytoplas-
mic region in various contexts, although it is not clear whether
synectin is always involved.
There are several X-ray crystal structures available that describe
either the isolated NRP1 b1 domain or various combinations ofa1
a2
(a) (b
b1
b2
c
FIGURE 2
Topology and domain organisation of the NRP ectodomain. (a) A ribbon diagram of 
is based on the NRP2 chain from the crystal structure of NRP2 in complex with a sem
not yet been obtained. No crystal structure of the c domain is available and a put
structure of the MAM domain from protein phosphatase m (PDB 2C9A). (b) VEGF1
superimposed over the b1 domain from the a1a2b1b2 structure shown in (a).
450 www.drugdiscoverytoday.comtandem NRP1 (and NRP2) domains (i.e. b1b2, a1a2 and a1a2b1)
[76–78] (Fig. 2a). These structures have provided valuable informa-
tion that has directed the development of NRP-targeted therapeu-
tics. Several structures describe complexes of NRP domains with
anti-NRP Fab fragments that interfere with either semaphorin or
VEGF binding. Although biochemical evidence had already indi-
cated that VEGF165 binds to the b1 domain of NRP1 via its C-
terminal tail region, the first atomic model for this ligand–receptor
interaction was derived from the crystal structure of a complex
between NRP1 tandem b1b2 domains and Tuftsin – an immunor-
eactive tetrapeptide that is produced by proteolysis of IgG heavy
chain Fc fragments [77,79]. The Tuftsin amino acid sequence, Thr-
Lys-Pro-Arg, is similar to the C-terminal tail of VEGF165, Lys-Pro-
Arg-Arg. The NRP1–Tuftsin structure enables the prediction of the
mode of VEGF binding via the conserved carboxy-terminal Arg
residue which, with specific electrostatic, H-bonding and van der
Waals contacts, nestles in a shallow binding site on the b1 domain
surface (Fig. 3a). The rest of the peptide extends away from the
groove formed by the b-strand-connecting loops of the b1 domain
b-sandwich fold. The location of the interaction site is analogous
to the ligand-binding region for other examples of discoidin
domains including those found in coagulation factors
[77,80,81]. An interesting feature of the NRP1–Tuftsin structure
is an extensive interface between the b1 and b2 domains that
suggests a ‘stable’ relative orientation of these modules in the NRP
extracellular region. In all subsequently determined crystal struc-
tures of NRP1 and NRP2 constructs the organization of this inter-
face is conserved (Figs 2a and 3). The presence of an extensive)
VEGF165-HBD
Drug Discovery Today 
domains a1a2b1b2 is shown with each domain coloured separately. The figure
aphorin-blocking Fab (not shown; PDB 2QQL). A similar structure for NRP1 has
ative topology of this domain is shown in parentheses based on the crystal
65-HBD (magenta) and the b1 domain from the fusion protein structure are
Drug Discovery Today  Volume 18, Numbers 9/10 May 2013 REVIEWS
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FIGURE 3
(a) Binding of Tuftsin to NRP1 b1b2 domains (PDB 2ORZ). The peptide (ball-and-stick representation) sits in a groove on the top of the b1 domain. The ribbon
diagram of NRP1 is coloured as rainbow from the N (blue) to the C (red) terminus of the polypeptide. (b) Surface representation of the NRP2 a1a2b1b2 monomer.
(c) Putative dimer of the NRP2 a1a2b1b2 structure based on the crystallographic symmetry contacts. The crystallographic interface that results in a dimer
formation was observed in two different crystal forms of NRP2 suggesting that this type of interaction might exist in a solution before crystallisation; however,
there is no direct confirmation that this dimerisation, mediated by reciprocal contacts between a1 domains, is the biologically relevant form of NRP. Grey circles
indicate areas engaged in binding to the C-terminus of the VEGF165-HBD.
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domain combination [76]. In general, the packing of all domains
within the context of longer polypeptide NRP constructs (i.e.
a1a2b1 or a2b1b2) is conserved irrespective of crystal symmetry,
implying that even though the NRPs possess, in sequence terms, a
modular organisation the tertiary domain architecture is well
defined and probably presents defined orientations of outer faces
for interaction with protein partners (Fig. 3). With exception of the
relatively small domain interface between domains a1 and a2,
every conformational change involving disruption of the other
interdomain contacts would probably incur a large energetic
penalty.
Binding of VEGF165 to NRPs is dependent upon the presence of
the VEGF heparin-binding domain (HBD) encoded by exons 7 and
8 of the VEGF gene [77,82,83]. By contrast, the VEGFR2 binds
VEGF165 at a site that spans a region encoded by exons 2 to 5 [84–
86]. A prevalent model for the tertiary complex formed between
VEGF165, VEGFR2 and NRP1 unites the two binding modes by
suggesting that VEGF165 acts as a bridge between the two receptor
ectodomains (Fig. 1). However, the model does not differentiate
between scenarios where NRP and VEGFR2 are present on the same
or on neighbouring cells (Fig. 1). Furthermore, it appears that
binding of VEGF165 to NRP1 is required for the formation of
detectable levels of complexes between VEGFR2 and NRP1 [87–
90] and that the PDZ-binding domain of NRP1 is indispensable for
NRP1–VEGFR2 complex formation [74].
Recently, in an attempt to gain an insight into the NRP–VEGF
interaction the crystal structure of a fusion protein was deter-
mined, where the polypeptide sequence corresponding to
VEGF165–HBD was appended to the C-terminus of the NRP1b1 domain [91]. The fusion protein forms a homodimer such that
the C-terminus of VEGF165–HBD, comprising two Cys-bridged
modules, binds to the ligand-binding groove of the b1 domain
of the neighbouring molecule in the asymmetric unit. The struc-
ture of this chimeric protein provides some additional information
with respect to the mode of VEGF165–HBD binding to NRP1 b1
domain. However, it is possible that the orientation of the HBD
with respect to the b1 domain might be restricted by the covalent
link of HBD to the C-terminus of the neighbouring b1 domain, and
influenced by crystal packing constraints (Fig. 2b). Based on this
structure, and in the absence of definitive information about the
segmental flexibility of VEGF165, it is difficult to extrapolate from
this result exactly how the full-length VEGF165 homodimer inter-
acts with intact NRP1.
So far, very little is known about the structure of the NRP c
(MAM) and intracellular domains. Presently, there are only two
MAM domain structures deposited in the Protein Data Bank (PDB),
both of which are common to the receptor protein tyrosine
phosphatase m [92]. Although in the latter case the all-b domain
is heavily glycosylated, there are no recognisable sequence motifs
within the NRP1 and NRP2 MAM domains that suggest the pre-
sence of glycosylation sites. However, it has been demonstrated
that NRP1 has an appended glycosaminoglycan – dominated by
either heparan sulphate or chondroitin sulphate – attached at
Ser612 which resides between the b2 and c domains [68,93].
Interestingly, this NRP1 glycosylation, that as much as doubles
the molecular mass of the polypeptide, has a profound effect on
signalling. Although the effect of glycosylation on VEGF-depen-
dent signalling remains to be investigated in vivo, it has
been shown that the presence of chondroitin sulphate on NRP1www.drugdiscoverytoday.com 451
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glioma cells [68] and that the different composition of the NRP1
glycosaminoglycan in endothelial and smooth muscle cells leads
to opposing responses to VEGF [93]. Furthermore, it has also been
observed that the presence of heparin in NRP1 binding assays
results in increased affinity for VEGF165 [94,95]. The mechanistic
basis for this enhancement and, in particular, whether this is
different for covalently versus exogenous non-covalently attached
GAGs is currently unclear.
A similarly unresolved issue is the structural nature of the NRP
cytoplasmic domain. Standard secondary structure prediction
algorithms suggest an absence of a significant quotient of regular
structure. It is therefore tempting to assign this region as an
intrinsically disordered polypeptide that perhaps adopts a specific
conformation only in a context of a complex with an interaction
partner. To date, the only protein identified to interact with the
cytoplasmic NRP domain is synectin which, as described above,
binds to the NRP C-terminal Ser-Glu-Ala tail through its PDZ
domain [73,74]. Although the structure of the NRP intracellular
domain is not known, the C-terminal Ser-Glu-Ala sequence does
have the typical sequence characteristics of a PDZ domain-binding
motif. In other cases PDZ domains bind to their partners by
extension of a b-sheet through the addition of an antiparallel b-
strand constituting the C-terminal tail of the protein ligand [96].
Whether synectin is constitutively bound to NRPs in the cell or
whether additional proteins contribute to NRP-dependent mem-
brane-associated signalling complexes is not currently known.
NRP-targeting strategies
The demonstrated involvement of NRP in the pathogenesis of
cancer has catalysed interest in targeting this molecule to combat
the disease. The modular organisation of the protein offers several
avenues for attack, such as the blocking of agonist–NRP interac-
tion, interference of NRP association with partner receptors (e.g.
VEGFR2) independent of ligand binding and inhibition of the
function of the intracellular NRP-signalling domain. In addition to
experimental approaches based upon these concepts, computer
simulations have also been employed to predict the most efficientEG00229
Y297
Y353
D320
(a) (b)
FIGURE 4
Ligand-binding pocket of the NRP1 b1 domain. (a) Stick representation of small mo
labelled. (b) Superposition of Tuftsin molecule (sticks, green) and VEGF165-HBD (ma
domains from the corresponding structures were not included in the figure for clari
among three structures are negligible.
452 www.drugdiscoverytoday.commethod for targeting VEGF–receptor interactions [97,98]. Using an
in silico model of VEGF interactions with endothelial cell receptors
that includes experimental estimates of the rate of VEGFR2–NRP
coupling by VEGF165 the authors concluded that blockade of NRP–
VEGFR interaction might provide the most effective decrease in
VEGF–VEGFR2 signalling [98].
Current efforts to target NRPs, and NRP1 in particular, have
focused on the specific interaction with the exon 7-8-encoded
region of VEGF165. Researchers at Genentech (http://www.gene.
com/gene/index.jsp) have developed a range of anti-NRP1 and
anti-NRP2 monoclonal antibodies that block interaction with
VEGF165 and semaphorins [12,76,99], and are undertaking clinical
trials to test the effectiveness of these monoclonal antibodies in
cancer treatment either as single agents or combination therapies.
An antibody to NRP2 that blocks VEGF-C binding has also been
reported [100]. Others have identified specific peptides and pepti-
domimetic inhibitors of VEGF165–NRP binding with antiangio-
genic activity [101–105]. All of these molecules are competitive
inhibitors of VEGF165 binding and were able to reduce downstream
VEGF signalling as demonstrated by reduced VEGFR2 tyrosine
phosphorylation. Although peptides are not considered to be
viable drug candidates they provide a starting point for struc-
ture-based design of peptidomimetics and small molecule inhibi-
tors. Giordano et al. employed a method of amino acid
retroinversion that involves substitution of D- for L-amino acids
and sequence reversal, to generate the potent peptidomimetic D-
(Leu-Pro-Arg) [105]. In initial studies this D-tripeptide was resistant
to proteolysis and exhibited antiangiogenic activity mediated
through NRP1 (and VEGFR1) based on in vivo assays in three
animal models of cancer and retinopathy. In addition, a synthetic
peptide targeting the transmembrane domain of NRP1 showed
antitumour activity [106]. A synthetic oligonucleotide (G18) has
also been reported to bind NRP1 resulting in receptor internalisa-
tion and inhibition of angiogenesis [107].
The first non-peptidic small molecule antagonist of NRP1 func-
tion has recently been reported by researchers at Ark Therapeutics
(http://www.arktherapeutics.com/main/index.php) [108] (Fig. 4).
Starting from the previously characterised bicyclic peptide EG3287Drug Discovery Today 
lecule VEGF antagonist EG00229 (grey). Key residues in the binding pocket are
genta) on the structure of the NRP1 b1/EG00229 (PDB 3I97) complex. The b1
ty. The differences in the side-chain conformations of the b1 domain residues
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VEGF-A165, the small molecule inhibitor EG00229 was developed.
Mutagenesis, X-ray crystallography and NMR spectroscopy were
used to show that EG00229 binds to the targeted pocket on the b1
domain of NRP1 (Fig. 4). The compound exhibits activity consis-
tent with inhibition of VEGF-A165 binding to NRP1 and decreases
VEGFR2 phosphorylation and cell migration in vitro. EG00229 is
also reported to demonstrate activity against tumour cells by
enhancing the cytotoxic effect of the chemotherapeutic drugs
paclitaxel and 5-fluorouracil. Currently, EG00229 is a valuable
tool for probing the molecular biology of NRP1 function; other
more potent compounds with a superior pharmacokinetic profile
are being developed by the same team.
Although co-immunoprecipitation experiments have demon-
strated association between NRP and VEGFRs [87,88], the lack of
biophysical and structural data describing the molecular basis of
putative protein–protein interaction surfaces between NRP and
VEGFR2, or other receptor tyrosine kinases, creates an obstacle to
the formulation of strategies to target NRP function. For example,
it would be helpful to understand better the role of the NRP MAM
domain and its putative interaction with the membrane-proximal
region of the VEGFR2 ectodomain. Analysis of the dimeric struc-
ture of the membrane-proximal domain D7 of VEGFR2 [109]
suggests that this domain is crucial for receptor signalling. It
would be reasonable to suppose that the (agonist-dependent)
proximal location of the MAM domain of associated NRP – in
addition to the potential role of the latter in NRP dimerisation on
the cell surface [83,110] – could promote interaction with VEGFR2
D7 or other domains and thereby bring the NRP cytoplasmic
region within the orbit of the VEGFR kinase domain. Finally, a
better understanding of the contribution of NRP to intracellular
signal transduction, through complex formation with proteins
that associate with the intracellular domain, could provide addi-
tional scope for the development of therapeutic approaches to
address the angiogenesis-related and -independent functions
of NRPs.
Additional application of NRP1-targeting peptides
An important property of NRP1-binding peptides has emerged that
could have significant implications for cancer drug targeting. A
series of investigations using phage particle libraries that were
initiated to search for tissue-penetrating peptides led to the obser-
vation that short peptides with basic (Arg or Lys) residues at the C-
terminus are readily internalised. To emphasise the requirement
for the basic residues being located at the C-terminus this activity
was named the ‘C-end rule’ [111,112]. It was shown that inter-
nalisation of these peptides is mediated by NRP1 and, because
NRP1 is upregulated in many cancer cell lines, this activity is being
explored as a mechanism for the targeted delivery of therapeuticand diagnostic agents to tumours [113,114]. For example, when
pro-apoptopic amino acid sequences were fused to NRP1-binding
peptides they were not only internalised but also exhibited a
potent antileukaemia cell effect [114]. Furthermore, a recent report
showed that gold nanoparticles could be functionalised with
NRP1-targeting peptides to effect internalisation [115]. Double-
decorated gold nanoparticles, carrying a therapeutic p53-stabilis-
ing peptide alongside the NRP-targeting peptide, showed promis-
ing in vitro anticancer activity. Although the development of this
NRP1-dependent drug delivery system is at an early stage, this
offers significant promise for the targeted application of multi-
functional agents with potential in areas as diverse as imaging,
diagnosis and combination therapy.
Concluding remarks
This account introduced the role of VEGFs in signalling via the
principal class of receptor (the VEGFRs) – signalling events that
provide the most direct opportunity for the therapeutic blockade
of angiogenesis. During recent years, drug discovery efforts in this
area have been substantial, with marketed drugs available for
oncology and ophthalmology indications, and are continuing
as evidenced by a number of ongoing clinical trials. Experience
has shown that these agents are associated with variable efficacy
and various side-effects. We have described the emergence of the
co-receptor role of the NRPs that also bind a subset of VEGF
isoforms. The contribution that NRPs make to VEGF signalling,
whether synergistic or otherwise, adds complexity to the VEGF
interactome yet, at the same time, provides a secondary means to
target VEGF signalling in disease. The acknowledged role of NRPs
in cell migration, along with the role in VEGF signalling, suggests
that a different spectrum of responses could emerge by targeting
this axis. Early efforts have demonstrated the potential for drug
development targeted to VEGF–NRP interactions, and this is likely
to expand as further understanding of the structural and biochem-
ical aspects of these interactions becomes available. Moreover, new
discoveries concerning the function of VEGFs and NRPs, such as
the determination of the ‘stemness’ of skin cancer cells [53] and
endothelial lipid transport [40,116] relevant to type II diabetes,
will probably provide additional avenues to exploit drug discovery
efforts in this niche.
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